PureTech Health plc (NASDAQ:PRTC - Get Free Report)'s stock price was down 3.8% during trading on Friday . The stock traded as low as $22.50 and last traded at $22.50. Approximately 2,784 shares changed hands during trading, a decline of 33% from the average daily volume of 4,174 shares. The stock had previously closed at $23.39.
Wall Street Analysts Forecast Growth
Several analysts have issued reports on the stock. Leerink Partnrs raised shares of PureTech Health to a "strong-buy" rating in a research note on Monday, September 9th. Leerink Partners began coverage on PureTech Health in a research note on Monday, September 9th. They set an "outperform" rating and a $45.00 price target for the company.
Read Our Latest Analysis on PRTC
PureTech Health Stock Performance
The stock's 50 day moving average price is $20.88 and its 200-day moving average price is $23.12.
Institutional Trading of PureTech Health
A hedge fund recently bought a new stake in PureTech Health stock. Birch Hill Investment Advisors LLC purchased a new position in shares of PureTech Health plc (NASDAQ:PRTC - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 302,000 shares of the company's stock, valued at approximately $7,550,000. Birch Hill Investment Advisors LLC owned 1.26% of PureTech Health as of its most recent SEC filing. 0.04% of the stock is currently owned by hedge funds and other institutional investors.
PureTech Health Company Profile
(
Get Free Report)
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
See Also
Before you consider PureTech Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.
While PureTech Health currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
